Partnering opportunity

Control of neurodegenerative diseases with benzothiazole-benzamide derivatives.


A Spanish Research Public Organization has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This inhibitory activity makes them useful in the treatment of neurodegenerative diseases affected by this enzyme, among which Parkinson's disease and Alzheimer's disease stand out. Pharmaceutical companies interested in the development and commercialization of these compounds under a patent license are sought.

Partner sought

Industrial partners from pharmaceutical industry are being sought to develop and commercialize the compounds through a patent licence agreement.


Neurodegenerative diseases, currently increasing, show as a common characteristic a progressive loss of neurons in specific regions of the nervous system and the deterioration of cognitive and motor functions. The lack of a specific treatment in most of them leads to the continuous search for new therapeutic targets. LRRK2 is a protein that has been classified as a member of the ROCO superfamily (Ras-like GTPase). Its physiological role is not well determined, but it has become an interesting target for neurodegenerative diseases, especially Parkinson's disease. It may also be related to other pathologies in which the tau protein is affected, as well as to the inflammatory response, oxidative stress, synaptic and mitochondrial dysfunctions and neurogenesis in adults. Because of the interest in LRRK2 as a therapeutic target for neurodegenerative diseases, inhibitors of this enzyme have been found that would be potential treatments, but most of these compounds present the difficulty of not crossing the blood-brain barrier or being less selective towards other protein kinases, which is an important problem in drug candidates for the treatment of diseases of the central nervous system (CNS). Researchers have developed compounds with a privileged structural core that makes them selective inhibitors of the LRRK2 protein, and capable of crossing the blood-brain barrier. The authors have shown the neurogenic activity of these compounds as well as their involvement in neuroprotection against the phosphorylation of the tau protein. The Spanish research center has a broad experience in developing novel compounds to be tested as potential candidates to treat neurodegenerative pathologies. The Spanish research center is searching for a company interested in the development and commercialization of these novel compounds under a license agreement. The compounds have only been tested at a laboratory scale, therefore some further development might be needed and the Spanish research center could collaborate with the company in that project.

Advantages and innovations

These molecules can cross the blood-brain barrier, which is an additional advantage of the compounds when used in therapeutic treatments of diseases related to the central nervous system. They can be presented in the most suitable pharmaceutical formulation for each treatment.

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company